FDA Advisory Committee recommends Repatha (evolocumab) for use for homozygous familial hypercholesterolaemia and heterozygous familial hypercholesterolaemia-Amgen

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA has voted 15-0 to recommend for Repatha (evolocumab) from Amgen as a treatment for patients with homozygous familial hypercholesterolaemia, and 11-4 in favour of its use in those with the less rare heterozygous familial hypercholesterolaemia form (HeFH).Use of Repatha is proposed to be initially restricted to patients at highest risk, until longer-term cardiovascular outcomes data is available.